Smith Chas P & Associates Pa Cpas 13F: Cuts JNJ Stake by $1.8M

Smith Chas P & Associates Pa Cpas trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% during the quarter, according to a Form 13F filed with the Securities and Exchange Commission on October 22, 2026. The filing showed the firm selling 7,129 shares to end the period with 238,267 shares valued at approximately $60.9 million.

JNJ Johnson & Johnson

$257.78 ▲ +26.32% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Smith Chas P & Associates Pa Cpas's Johnson & Johnson Position

The firm reduced its exposure to the healthcare stalwart by shedding a fraction of its total investment. Prior to the trade, the investor held 245,396 shares. The remaining block of 238,267 shares reflects a 2.9% decrease, leaving the portfolio with a sizable stake in the drug maker as of the October filing date when the stock closed at $264.19.

Other Institutional Activity in Johnson & Johnson

Other institutional investors adjusted their positions around the same time. Accurate Wealth Management grew its holdings by 5,437 shares, ending with 37,817 shares worth about $9.4 million. First Citizens Bank & Trust lifted its stake by 22,136 shares to hold 52,947 shares valued at roughly $14.0 million. Zwj Investment Counsel added 6,670 shares, closing the period with 231,462 shares worth about $61.3 million. On the other side, Fort Washington Investment Advisors reduced its position by 539,918 shares to finish with 404,591 shares valued at $107.1 million, and Fjarde Ap-Fonden trimmed 151,529 shares to hold 1,105,140 shares worth about $292.6 million.

Johnson & Johnson Stock Up 1.2%

Johnson & Johnson shares recently traded around $262.46, sitting below the closing price of $264.19 recorded on the filing date. The stock trades below its 50-day moving average but remains above its 200-day moving average.

Recent Earnings

Johnson & Johnson generated trailing twelve month revenue of $99.3 billion and net earnings of $6.59 per share. The healthcare company posted a net profit margin of 16.2% and a return on equity reflecting stable profitability. The next quarterly earnings report is scheduled for release on January 26, 2027.

Dividend

The company pays an annual dividend rate of $5.36 per share, providing a dividend yield of 2.08% based on recent share levels. The payout is supported by a dividend payout ratio of 60.7%.

Insider Buying and Selling at Johnson & Johnson

Company insiders were active in the market ahead of the filing. Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, totaling $4.1 million. Chief Executive Officer Joaquin Boix Duato disposed of 123,291 shares on August 13, 2026, with a total value of $32.2 million. Officer Jennifer L Taubert parted with 15,000 shares on August 17, 2026, at an average price of $263.36, realizing nearly $4.0 million. Later, on September 2, 2026, officer Timothy Schmid sold 33,597 shares at an average price of $274.74 for a total value of $9.2 million.

Analysts Set New Price Targets

Wall Street analysts updated their views on the stock through mid-October. Leerink Partners maintained an outperform rating on October 14 with a target of $272. Wells Fargo maintained an overweight rating on October 14 with a $275 target, and later raised it to $287 on October 16. RBC Capital maintained an outperform rating on October 14 with a $280 target. Morgan Stanley maintained an overweight rating on October 15 with a price target of $292. Across the broader community, the stock holds a consensus buy rating with a mean price target of $279.41.

About Johnson & Johnson

Johnson & Johnson operates as a worldwide healthcare company engaged in researching, developing, and manufacturing health products. The enterprise runs through two primary segments: Innovative Medicine and MedTech. Its operations span pharmaceuticals and medical devices used by patients and providers globally.

Bottom Line

Institutional adjustments in Johnson & Johnson highlight ongoing portfolio rebalancing among major wealth managers. Investors will look toward the upcoming earnings release on January 26, 2027, for further insight into revenue trends and segment performance.